Monitoring and biopsy;Monitorización y biopsia

Gastroenterologia y Hepatologia

Volumn 29, Issue SUPPL. 2, 2006, Pages 121-124

  Morillas, R M ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; RIBAVIRIN; THYROID ANTIBODY; THYROTROPIN;

ANTIVIRAL THERAPY; CONFERENCE PAPER; GENOTYPE; HEPATITIS; HUMAN; IMMUNE DEFICIENCY; LIVER BIOPSY; LIVER FIBROSIS; PROGNOSIS; THYROID FUNCTION;

EID: 34547913837     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13097644     Document Type: Conference Paper

References (16)

1. Consensus Statement. EASL International Consensus Conference on Hepatitis C. Paris, February 26-28, 1999. J Hepatol. 1999;30:956-61.
2. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004;39(4):1147-71.
3. Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol. 2003;38:S104-18.
4. National Institutes of Health. Consensus Development Conference Statement. Management of hepatitis C. June 10-12, 2002. Hepatology. 2002;36(Suppl 1):S3-20.
5. Fried M, Shiffman M, Reddy R, Smith C, Marinos G, Goncales F, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82.
6. Davis G, Wong J, McHutchison J, Manns M, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38(3):645-52.
7. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36:S152-60.
8. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, El-Kanary SS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S161-72.
9. Almasio PL, Niero M, Angioli D, Ascione A, Gullini S, Minoli G, et al. Experts' opinions on the role ef liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (AIGO). J Hepatol. 2005;43:381-7.
10. Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two o three specimens are taken. Postgrad Med J. 1992;68:964-7.
11. Bravo AK, Seth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
12. Regev A, Berho M, Jeffers JL, Milikowski C, Molina EG, Pyrsopoulos, et al. Sampling error and intraobserver variation in the liver biopsy in patients with chronic HCV infections. Am J Gastroenterol. 2002;97:2614-8.
13. Soloway RD, Baggenstoss AH, Schoenfield LJ, et al. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis. 1971;16:1082-7.
14. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-50.
15. Desmet VJ, Gerber MA, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-20.
16. National Institute of Health. Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology. 1997;26:S5-10.